ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2026-09-15
Target enrollment:
Participant gender:
Summary
This is a study to test the safety and efficacy with the combination of a next generation
anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant
ovarian cancer patients.